Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice

* Participants voluntarily signed a patient authorization form to use and disclose personal health information (or informed consent, where applicable). * Age \>= 18 years at the time of the enrollment. * Diagnosis of active NIIPP uveitis as defined by the presence of at least 1 of the following parameters: 1. Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion 2. \>= 2+ anterior chamber cells \[Standardization of Uveitis Nomenclature (SUN) criteria\] 3. \>= 2+ vitreous haze \[National Eye Institute (NEI)/SUN criteria\] * Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional and/or reimbursement guidelines. * Decision on the treatment with Humira® was made prior to any decision to approach the patient to participate in this study.

* Participants who cannot be treated with Humira® according to the local Humira® SmPC and/or local professional and reimbursement guidelines. * Prior treatment with Humira®, including current course of Humira® started prior to baseline visit assessments. * Participants currently participating in other clinical research. * Participants who are unwilling or unable to complete the quality of life and other patient reported questionnaires.